Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gianna Tempera is active.

Publication


Featured researches published by Gianna Tempera.


Antimicrobial Agents and Chemotherapy | 2000

Ofloxacin-Loaded Liposomes: In Vitro Activity and Drug Accumulation in Bacteria

Pio Maria Furneri; Massimo Fresta; Giovanni Puglisi; Gianna Tempera

ABSTRACT Different ofloxacin-loaded unilamellar vesicles were prepared by the extrusion technique, and their antimicrobial activities were determined in comparison to those of the free drug by means of MIC determinations with both American Type Culture Collection standards and wild-type bacterial strains (six strains of Enterococcus faecalis, seven strains of Escherichia coli, six strains of Staphylococcus aureus, and six strains ofPseudomonas aeruginosa). The accumulation of ofloxacin and liposome-ofloxacin was measured by determining the amount of the drug inside the bacteria as a function of time. Encapsulated fluoroquinolone yielded MICs which were at least twofold lower than those obtained with the free drug. In particular, liposomes made up of dimyristoylphosphatidylcholine-cholesterol-dipalmitoylphosphatidylserine and dimyristoylphosphatidylcholine-cholesterol-dihexadecylphosphate (4:3:4 molar ratio) provided the best improvement in antimicrobial activity against the various bacterial strains investigated. The liposome formulation produced higher intracellular fluoroquinolone concentrations than those achieved simultaneously with the free drug in both E. coli and P. aeruginosa.


International Journal of Pharmaceutics | 1995

Formulation parameters of fluoroquinolone-loaded liposomes and in vitro antimicrobial activity☆

Giovanni Puglisi; Massimo Fresta; Mazzone G; Pio Maria Furneri; Gianna Tempera

Abstract To load pefloxacin and ofloxacin in liposomes, two preparation procedures were carried out, leading to the formation of multilamellar vesicles (MLVs) or reverse-phase evaporation vesicles (REVs). MLVs were able to entrap greater amounts of the two drugs than REVs, especially when the drugs were co-dissolved with the lipid mixture in the organic phase. The encapsulation efficiency was influenced by the presence of a negatively charged lipid in the liposome composition: the greater the content of charged lipidic compound, the larger is the amount of drug entrapped. Among the charged systems, a dipalmitoylphosphatidylcholine-cholesterol-dihexadecyl phosphate mixture (4:3:4 molar ratio) showed the highest trapping capacity. The fluidity of the bilayer could also influence the encapsulation efficiency. In fact, the increase in encapsulation capacity for the lecithin-cholesterol-dihexadecyl phosphate mixture (4:3:4 molar ratio) conformed to the following order: dipalmitoylphosphatidylcholine > dimyristoylphosphatidylcholine > egg phosphatidylcholine. Variation in pH values led to different encapsulation efficiency and release rate. In vitro experiments on the antimicrobial activity of the encapsulated fluroquinolones compared to the free drug demonstrated a reduction of at least 50% of the minimal inhibitory concentration.


Gynecologic and Obstetric Investigation | 2010

Management of aerobic vaginitis.

Gianna Tempera; Pio Maria Furneri

Aerobic vaginitis is a new nonclassifiable pathology that is neither specific vaginitis nor bacterial vaginosis. The diversity of this microbiological peculiarity could also explain several therapeutic failures when patients were treated for infections identified as bacterial vaginosis. The diagnosis ‘aerobic vaginitis’ is essentially based on microscopic examinations using a phase-contrast microscope (at ×400 magnification). The therapeutic choice for ‘aerobic vaginitis’ should take into consideration an antibiotic characterized by an intrinsic activity against the majority of bacteria of fecal origin, bactericidal effect and poor/absent interference with the vaginal microbiota. Regarding the therapy for aerobic vaginitis when antimicrobial agents are prescribed, not only the antimicrobial spectrum but also the presumed ecological disturbance on the anaerobic and aerobic vaginal and rectal microbiota should be taken into a consideration. Because of their very low impact on the vaginal microbiota, kanamycin or quinolones are to be considered a good choice for therapy.


Antiviral Research | 2000

Anti-rhinovirus activity of 3-methylthio-5-aryl-4-isothiazolecarbonitrile derivatives

Adriana Garozzo; C.C.C Cutrı̀; A. Castro; Gianna Tempera; Francesco Guerrera; Maria Sarvà; Ernesto Geremia

A series of 3-methylthio-5-aryl-4-isothiazolecarbonitriles has been evaluated as anti rhinovirus agents against a panel of 17 representative human rhinovirus (HRV) serotypes, belonging to both A and B groups. No anti rhinovirus activity was detected for 3-methylthio-5-phenyl-4-isothiazolecarbonitrile (IS-2). Isothiazole derivatives with bulky substituents (O-Bn or O-But groups) on the para position of the phenyl ring were the most effective compounds of this series. In fact, a reduction in virus-induced cytopathogenicity was demonstrated for the O-Bn substituted IS-50 compound against the majority (88%) of the rhinoviruses tested, whereas the compound with an O-Ts group (IS-44) was found to be a specific inhibitor of group B serotypes, exhibiting the lowest IC(50) against HRVs type 2, 85 and 89. Our studies on the mechanism of action of IS-44 demonstrated that it prevents the thermal inactivation of HRV 2 infectivity, probably due to a conformational shift in the viral capsid and a decrease in affinity for the cellular receptor, resulting in an inhibition of attachment of the virions.


Antiviral Research | 2002

Synthesis of new 3-methylthio-5-aryl-4-isothiazolecarbonitriles with broad antiviral spectrum.

C.C.C Cutrı̀; Adriana Garozzo; Maria A. Siracusa; A. Castro; Gianna Tempera; Maria Sarvà; Francesco Guerrera

The isothiazole derivative 3-methylthio-5-(4-OBn-phenyl)-4-isothiazolecarbonitrile, coded IS-50, which in previous studies had exhibited a broad antipicornavirus spectrum of action, was selected as the model for the synthesis of a new series of 3-methylthio-5-aryl-4-isothiazolecarbonitriles. These compounds were prepared in good yield (from 66 to 82%) by alkylation of 3-methylthio-5-(4-hydroxyphenyl)-4-isothiazolecarbonitrile with suitable bromides in the presence of acetone; only the 4-cyanophenoxy derivatives were obtained in a yield of less than 30%. All the compounds were screened against a panel of 17 representative human rhinovirus (HRV) serotypes belonging to both A and B groups, enteroviruses polio 1, ECHO 9 and Coxsackie B1, cardiovirus EMC, measles virus, and herpes simplex virus type 1 (HSV-1). Our results demonstrate that HRV 86 (group A) and HRVs 39 and 89 (group B) are the rhinovirus serotypes more susceptible to the action of these compounds. Isothiazole derivatives with a longer intermediate alkyl chain exhibited good activity against polio 1 and ECHO 9. The compound bearing a butyl group between the two phenoxy rings showed the lowest IC(50) against Coxsackie B1 and measles viruses. No activity against HSV-1 was detected with any of the compounds screened.


International Journal of Immunopathology and Pharmacology | 2010

Inhibitory Activity of Cranberry Extract on the Bacterial Adhesiveness in the Urine of Women: An Ex-vivo Study

Gianna Tempera; S. Corsello; Genovese C; F.E. Caruso; Nicolosi D

Strains of uropathogenic E. coli are responsible for approximately 90% of community-acquired, uncomplicated cystitis, and fimbriae represent the adhesive factors enabling E. coli to be anchored to uroepithelial cells in the first step of the infectious process. Recently, a few studies have shown that a correlation between the consumption of cranberry (Vaccinium macrocarpon) and prevention of UTI is related to the ability of proanthocyanidins to reduce the bacterial adhesion to uroepithelial cells. In this study we evaluate the inhibitory activity of urine of healthy women treated with tablets containing cranberry extract on the adhesiveness of E. coli to uroepithelial human cells. Two groups of 12 female volunteers each, aged between 18 and 65 years, were enrolled, one group with negative history and one group with positive history of recurrent cystitis. Subjects were treated with the active product or placebo in a random, cross-over, double-blinded sequence for one week in each of the two treatment sequences. Urine samples were collected at the beginning and the end of each study period. Tests of bacterial adhesiveness were performed with two strains of E. coli (ATCC 25922 and ATCC 35218) on HT1376 human bladder carcinoma cells. Significant reductions of bacterial adhesiveness were observed in women who received cranberry extract (−50.9%; p<0.0001), regardless of their medical history and the treatment period in the cross-over sequence. No changes were observed with placebo (−0.29%; n.s.). This ex-vivo study showed that the assumption of cranberry extract in suitable amounts can have an anti-adhesive activity on uropathogenic E. coli.


Neuroepidemiology | 1998

A Neuroepidemiological Survey in Rural Bolivia: Background and Methods

Alessandra Nicoletti; A. Reggio; Alessandro Bartoloni; Gaetano Failla; Filippo Bartalesi; Mimmo Roselli; Herlan Gamboa; Esteban Salazar; Franco Paradisi; Gianna Tempera; Andrew J. Hall

A door-to-door survey was carried out in rural areas of the Cordillera province, Santa Cruz Department, Bolivia. A cluster sample of 10,124 inhabitants was selected. The aim was to determine the prevalence of the most common neurological diseases (epilepsy, stroke, parkinsonism and peripheral neuropathy) in this population using a modification of the World Health Organization screening instrument. 1,130 subjects screened positive and were then investigated by neurologists. In this paper we describe the background and methods of the survey and the characteristics of the population.


Bioorganic & Medicinal Chemistry | 1998

Synthesis and antiviral activity of a new series of 4-isothiazolecarbonitriles

Christian C. C. Cutri; Adriana Garozzo; Maria A. Siracusa; Maria Sarvà; Gianna Tempera; Ernesto Geremia; Maria R. Pinizzotto; Francesco Guerrera

A series of 4-isothiazolecarbonitriles was synthesized and screened for in vitro antiviral activity. The effect of various substituents on the phenyl ring, as well as the substitution of the phenyl for other aromatic and heteroaromatic rings, was examined to establish the requirements for optimum activity. The most active member of the series, 3methylthio-5-phenyl-4-isothiazolecarbonitrile, exhibited a high level of activity against enteroviruses polio 1 and ECHO 9. Preliminary studies on its mechanism of action indicated that this compound had an effect on an early event in the replication of poliovirus type 1.


Journal of Chemotherapy | 2006

Topical Kanamycin: an Effective Therapeutic Option in Aerobic Vaginitis

Gianna Tempera; G. Abbadessa; G. Bonfiglio; E. Cammarata; A. Cianci; S. Corsello; A. Raimondi; G. Ettore; D. Nicolosi; P.M. Furneri

Abstract Eighty-one patients with clinical diagnosis of aerobic vaginitis (AV) were included in the study. The patients were randomized for treatment, 45 with kanamycin (100 mg vaginal ovules for 6 days, consecutively) and 36 with meclocycline (35 mg vaginal ovules for 6 days, consecutively). The patients were examined before starting the study, 1-2 days after treatment and 30 days after the end of the study. At the first follow-up the patients showed different levels of symptom reduction. Reduction in the presence of leukocytes, vaginal mucosa burning and itching were statistically significant in the group treated with kanamycin with respect to the group treated with meclocycline. Moreover, there was also reduced isolation of Enterobacteriaeae (97%) in the group treated with kanamycin versus those treated with meclocycline (76%). At the second follow-up, vaginal homeostasis (normalization of pH and presence of lactobacilli) was more evident in the kanamycin-treated group. In conclusion, our data suggest that the topical use of kanamycin could be considered a specific antibiotic for the therapy of this new pathology.


Chemotherapy | 2005

Fosfomycin Tromethamine in Uncomplicated Urinary Tract Infections: A Clinical Study

Giovanni Bonfiglio; Roberto Mattina; Antonina Lanzafame; Esmeralda Cammarata; Gianna Tempera

The aim of our study was to verify if the empiric therapy with a single dose of 3 g fosfomycin tromethamine in patients with uncomplicated urinary tract infections (UTIs) was able to clinically resolveand to microbiologically eradicate the infection. A total of 387 out of the 400 patients (274 cases with acute and 113 cases with recurrent uncomplicated UTIs) were enrolled in the clinical study. Clinical and microbiological assessments were performed before and at 8–10 days after the administration. At follow-up high clinical recovery (88.9%) and bacteriological (94.9%) eradication rates were achieved. Gastrointestinal side effects were found in only 4.3% of patients. In conclusion, a single-dose administration regimen of fosfomycin tromethamine should be encouraged as a first choice of drug therapy for uncomplicated UTIs.

Collaboration


Dive into the Gianna Tempera's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Castro

University of Catania

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge